Table 1.
Demographical, clinical, and immunological characteristics of the study cohorts
| PsA (n = 34) | p | Abneg RA (n = 55) | p 1 | p 2 | p 3 | |||
|---|---|---|---|---|---|---|---|---|
| Naive (n = 12) | MTX-IR (n = 22) | Naive (n = 27) | MTX-IR (n = 28) | |||||
| Age, years (mean ± SD) | 54.75 ± 17.18 | 60.18 ± 9.81 | 0.47 | 52.41 ± 17.70 | 58.36 ± 16.58 | 0.16 | 0.68 | 0.77 |
| Female, n (%) | 4 (33.3) | 14 (63.6) | 0.10 | 23 (85.2) | 23 (82.1) | 0.76 | 0.001 | 0.14 |
| Disease duration, years (mean ± SD) | 0.80 ± 0.24 | 5.83 ± 3.68 | < 0.001 | 0.84 ± 0.95 | 5.68 ± 5.28 | 0.002 | 0.44 | 0.49 |
| DAS44 (mean ± SD) | 3.00 ± 0.42 | 3.34 ± 0.91 | 0.34 | 3.37 ± 1.05 | 3.22 ± 0.79 | 0.71 | 0.52 | 0.81 |
| DAPSA (mean ± SD) | 22.55 ± 8.38 | 28.04 ± 10.14 | 0.10 | – | – | – | – | – |
| SJC (mean ± SD) | 4.00 ± 2.67 | 6.43 ± 5.69 | 0.35 | 8.22 ± 7.95 | 7.15 ± 5.53 | 0.93 | 0.18 | 0.54 |
| TJC (mean ± SD) | 5.00 ± 3.16 | 7.00 ± 6.13 | 0.66 | 8.22 ± 7.86 | 8.44 ± 5.46 | 0.33 | 0.51 | 0.24 |
| ESR, mm/1st hour (mean ± SD) | 29.60 ± 36.94 | 29.10 ± 19.59 | 0.44 | 44.00 ± 25.40 | 37.04 ± 27.25 | 0.19 | 0.03 | 0.44 |
| CRP, mg/l (mean ± SD) | 16.70 ± 29.16 | 18.11 ± 23.41 | 0.70 | 16.99 ± 19.43 | 16.77 ± 24.23 | 0.77 | 0.72 | 1.00 |
| Ab positivity, n (%) | 0 (0.0) | 0 (0.0) | 1.00 | 0 (0.0) | 0 (0.0) | 1.00 | 1.00 | 1.00 |
Data presented in italics have p < 0.05
PsA psoriatic arthritis, RA rheumatoid arthritis, Ab autoantibody, DAS Disease Activity Score, DAPSA Disease Activity in PSoriatic Arthritis, SJC swollen joint count, TJC tender joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SD standard deviation, MTX-IR methotrexate inadequately responder, p naive PsA vs MTX-IR PsA, p1 naive Abneg RA vs MTX-IR Abneg RA, p2 naive PsA vs naive Abneg RA, p3 MTX-IR PsA vs MTX-IR Abneg RA